Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease.

导出原文传递

翻译打印收藏纠错

作者： Cristina M,Merkhofer ^[1] ; Boryana,Eastman ^[2] ; Isabella,Densmore ^[3] ; Lia M,Halasz ^[2] ; Tresa,McGranahan ^[4] ; Christina,Baik ^[5]

作者单位： Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA. Electronic address: cmerkhof@fredhutch.org. ^[1] Department of Radiation Oncology, University of Washington, Seattle, WA. ^[2] School of Medicine, University of Washington, Seattle, WA. ^[3] Alvord Brain Tumor Center, Department of Neurology, University of Washington, Seattle, WA. ^[4] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA. ^[5]

关键词 Central nervous system Epidermal growth factor receptor mutation Healthcare utilization Leptomeningeal Natural history Osimertinib

主题词癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);人类(Humans);肺肿瘤(Lung Neoplasms);脑膜癌病(Meningeal Carcinomatosis);突变(Mutation);蛋白激酶抑制剂(Protein Kinase Inhibitors);回顾性研究(Retrospective Studies)

DOI 10.1016/j.cllc.2022.03.013

PMID 35610115

发布时间 2022-08-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交